Vedolizumab

Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.

LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs. adalimumab and a comparable profile for ozanimod vs. vedolizumab.

LAS VEGAS – Physicians should remember there are many points to consider when selecting the right treatment for patients with ulcerative colitis, according to a presenter at the ACG Annual Scientific Meeting.

Higher visceral adipose tissue correlated with lower rates of inflammatory bowel disease remission among patients dosed with infliximab, vedolizumab or ustekinumab, according to Andres Yarur, MD, Medical College of Wisconsin.

Obesity was not associated with an increased risk for serious infection among patients with inflammatory bowel disease treated with biologics, according to research published in Clinical and Translational Gastroenterology.

Biologic infusions administered at home are associated with a 25% increased risk for hospital admission the same or next day, and a 28% higher risk for permanent discontinuation, compared with facility-given infusions, according to data.

Model-informed dosing of Entyvio provided data to maximize endoscopic remission rates among patients with Crohn’s disease, according to research published in Inflammatory Bowel Diseases.

In an exclusive video with Healio Gastroenterology, Benjamin Click, MD, Cleveland Clinic, spoke about the safety and efficacy of Stelara and Entyvio in elderly patients with Crohn’s disease.

Patients who received Remicade for inflammatory bowel disease had weakened anti-COVID-19 antibody responses following a single vaccination dose, according to research published in Gut.

Patients with ulcerative colitis treated with Entyvio had a lower risk for serious infections compared with those who received anti-TNF, according to study results.